J
Jorma Paavonen
Researcher at University of Helsinki
Publications - 437
Citations - 30837
Jorma Paavonen is an academic researcher from University of Helsinki. The author has contributed to research in topics: Chlamydia trachomatis & Population. The author has an hindex of 81, co-authored 435 publications receiving 29202 citations. Previous affiliations of Jorma Paavonen include University of Washington & Oslo University Hospital.
Papers
More filters
Journal ArticleDOI
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions
Luisa L. Villa,Gonzalo Perez,Susanne K. Kjaer,Jorma Paavonen,Matti Lehtinen,Nubia Muñoz,Kristjan Sigurdsson,Mauricio Hernández-Ávila,Finn Egil Skjeldestad,Steinar Thoresen,Patricia J. Garcia,Slawomir Majewski,Joakim Dillner,Sven Eric Olsson,Hseon Tay Eng,F. Xavier Bosch,Kevin A. Ault,Darron R. Brown,Daron G. Ferris,Laura A. Koutsky,Robert J. Kurman,Evan R. Myers,Eliav Barr,John W. Boslego,Janine T. Bryan,Mark T. Esser,Christine K. Gause,Teresa M. Hesley,Lisa Lupinacci,Heather L. Sings,Frank J. Taddeo,Annemarie R. Thornton +31 more
TL;DR: In young women who had not been previously infected with HPV-16 or HPV-18, those in the vaccine group had a significantly lower occurrence of high-grade cervical intraepithelial neoplasia related to HPV- 16 or HPV -18 than did those inThe placebo group.
Journal ArticleDOI
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.
Jorma Paavonen,Paulo Naud,Jorge Salmerón,Cosette M. Wheeler,Song-Nan Chow,D Apter,Henry C Kitchener,Xavier Castellsagué,Julio Cesar Teixeira,S R Skinner,James Hedrick,Unnop Jaisamrarn,Genara Limson,Suzanne M. Garland,Anne Szarewski,Barbara Romanowski,Fred Y. Aoki,Tino F. Schwarz,Willy Poppe,Franz X. Bosch,David Jenkins,Karin Hardt,Toufik Zahaf,Dominique Descamps,Frank Struyf,Matti Lehtinen,Gary Dubin +26 more
TL;DR: The HPV- 16/18 AS04-adjuvanted vaccine showed high efficacy against CIN2+ associated with HPV-16/18 and non-vaccine oncogenic HPV types and substantial overall effect in cohorts that are relevant to universal mass vaccination and catch-up programmes.
Journal ArticleDOI
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial
Jorma Paavonen,David Jenkins,F. Xavier Bosch,Paulo Naud,Jorge Salmerón,Cosette M. Wheeler,Song Nan Chow,D Apter,Henry C Kitchener,Xavier Castellsagué,Newton Sérgio de Carvalho,S. Rachel Skinner,Diane M. Harper,James Hedrick,Unnop Jaisamrarn,Genara Limson,Marc Dionne,Wim Quint,Bart Spiessens,Pascal Peeters,Frank Struyf,Susan L. Wieting,Matti Lehtinen,Gary Dubin +23 more
TL;DR: The adjuvanted HPV16/18 vaccine showed prophylactic efficacy against cervical intraepithelial neoplasia (CIN) 2+ associated with HPV16 or HPV18 and thus could be used for cervical cancer prevention.
Journal ArticleDOI
A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection.
Laura A. Koutsky,King K. Holmes,Cathy W. Critchlow,Claire E. Stevens,Jorma Paavonen,Anna Marie Beckmann,Timothy A. DeRouen,Denise A. Galloway,Debra A. Vernon,Nancy B. Kiviat +9 more
TL;DR: The cumulative incidence of cervical intraepithelial neoplasia at two years was 28 percent among women with a positive test for HPV and 3 percent among those without detectable HPV DNA.
Journal ArticleDOI
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up
Luisa L. Villa,Ronaldo L.R. Costa,Carlos Alberto Petta,Rosires Pereira de Andrade,Jorma Paavonen,O-E Iversen,S-E Olsson,J. Hoye,Margareta Steinwall,G. Riis-Johannessen,A. Andersson-Ellstrom,Kristina Elfgren,G. Von Krogh,Matti Lehtinen,Christian Malm,Gretchen M. Tamms,Katherine E.D. Giacoletti,Lisa Lupinacci,Radha Railkar,Frank J. Taddeo,Janine T. Bryan,Mark T. Esser,Heather L. Sings,Alfred Saah,Eliav Barr +24 more
TL;DR: A prophylactic quadrivalent HPV vaccine was effective through 5 years for prevention of persistent infection and disease caused by HPV 6/11/16/18, and this duration supports vaccination of adolescents and young adults.